News
MSLE
10.03
-0.40%
-0.04
Weekly Report: what happened at MSLE last week (0727-0731)?
Weekly Report · 6d ago
Weekly Report: what happened at MSLE last week (0720-0724)?
Weekly Report · 07/27 09:14
Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets
NASDAQ · 07/23 03:09
Weekly Report: what happened at MSLE last week (0713-0717)?
Weekly Report · 07/20 09:13
Weekly Report: what happened at MSLE last week (0706-0710)?
Weekly Report · 07/13 09:14
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal
NASDAQ · 07/10 16:10
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Satellos Bioscience (MSLE) and Intuitive Surgical (ISRG)
TipRanks · 07/09 11:40
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Benzinga · 07/08 13:34
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/08 12:05
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients
TipRanks · 07/08 10:57
Satellos Bioscience Announces Six-Month Interim Data From TRAILHEAD Evaluating SAT-3247 In Adults With Duchenne Muscular Dystrophy; All Four Participants Showed Decline In Fat Fraction As Measured By MRI
Benzinga · 07/08 10:35
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Barchart · 07/08 05:30
Weekly Report: what happened at MSLE last week (0629-0703)?
Weekly Report · 07/06 09:14
Guggenheim Keeps Their Buy Rating on Satellos Bioscience (MSLE)
TipRanks · 06/30 11:45
Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up
NASDAQ · 06/29 16:16
Satellos Bioscience's Duchenne Drug SAT-3247 Wins FDA Fast Track Designation
NASDAQ · 06/29 11:53
Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247
TipRanks · 06/29 11:29
Satellos Gets FDA Fast Track Status For Duchenne Drug
Benzinga · 06/29 11:15
Satellos announces Fast Track designation for SAT-3247
TipRanks · 06/29 11:15
Stocks in play: Satellos Bioscience Inc.
Barchart · 06/29 10:02
More
Webull provides a variety of real-time MSLE stock news. You can receive the latest news about Satellos Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About MSLE
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.